1. Home
  2. PRLD vs WETO Comparison

PRLD vs WETO Comparison

Compare PRLD & WETO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRLD
  • WETO
  • Stock Information
  • Founded
  • PRLD 2016
  • WETO 2019
  • Country
  • PRLD United States
  • WETO China
  • Employees
  • PRLD N/A
  • WETO N/A
  • Industry
  • PRLD Medicinal Chemicals and Botanical Products
  • WETO
  • Sector
  • PRLD Health Care
  • WETO
  • Exchange
  • PRLD Nasdaq
  • WETO NYSE
  • Market Cap
  • PRLD 73.7M
  • WETO 81.4M
  • IPO Year
  • PRLD 2020
  • WETO 2025
  • Fundamental
  • Price
  • PRLD $0.81
  • WETO $3.90
  • Analyst Decision
  • PRLD Strong Buy
  • WETO
  • Analyst Count
  • PRLD 2
  • WETO 0
  • Target Price
  • PRLD $4.50
  • WETO N/A
  • AVG Volume (30 Days)
  • PRLD 279.1K
  • WETO 22.1K
  • Earning Date
  • PRLD 05-06-2025
  • WETO 01-01-0001
  • Dividend Yield
  • PRLD N/A
  • WETO N/A
  • EPS Growth
  • PRLD N/A
  • WETO N/A
  • EPS
  • PRLD N/A
  • WETO N/A
  • Revenue
  • PRLD $7,000,000.00
  • WETO $6,326,827.00
  • Revenue This Year
  • PRLD N/A
  • WETO N/A
  • Revenue Next Year
  • PRLD N/A
  • WETO N/A
  • P/E Ratio
  • PRLD N/A
  • WETO N/A
  • Revenue Growth
  • PRLD N/A
  • WETO N/A
  • 52 Week Low
  • PRLD $0.61
  • WETO $3.10
  • 52 Week High
  • PRLD $6.80
  • WETO $4.28
  • Technical
  • Relative Strength Index (RSI)
  • PRLD 57.52
  • WETO N/A
  • Support Level
  • PRLD $0.71
  • WETO N/A
  • Resistance Level
  • PRLD $0.72
  • WETO N/A
  • Average True Range (ATR)
  • PRLD 0.08
  • WETO 0.00
  • MACD
  • PRLD 0.02
  • WETO 0.00
  • Stochastic Oscillator
  • PRLD 76.92
  • WETO 0.00

About PRLD Prelude Therapeutics Incorporated

Prelude Therapeutics Incorp is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.

About WETO WEBUS INTERNATIONAL LIMITED

Webus International Ltd operates on a business model of Mobility-as-a-Service to identify and solve inefficiencies associated with inflexible or low-quality public transportation and provide cost-efficient and customized mass transportation services under different scenarios with comprehensive digital platforms. It offers commute shuttle service, customized chartered bus service, packaged tour service and other service to customers.

Share on Social Networks: